{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:56:15Z","timestamp":1775577375637,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007750","name":"National Cheng Kung University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007750","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Appropriate treatments for nonopioid substance use are currently unavailable. Venlafaxine may reduce withdrawal from nonopioid substances, but the effects have not been evaluated. We aimed to investigate the association between venlafaxine use and the risk of withdrawal from nonopioid substances.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We linked Taiwan\u2019s National Health Insurance Research Database and the Taiwan Illicit Drug Issue Database from January 2012 to December 2019. We used a case-case-time-control study involving a case-crossover analysis and a control-crossover analysis consisting of future cases. The outcomes were withdrawal from substances and all-cause mortality. For each individual, venlafaxine use during the hazard period (day \u2212\u20098 to \u2212\u200967 before the outcome) was compared with that during the 60-day reference period (between days \u2212\u2009248 and \u2212\u2009307). Conditional logistic regression was used to determine odds ratios with 95% confidence intervals to evaluate the associations between outcome events and the use of venlafaxine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The participants\u2019 average age on the index date was 39.5\u00a0years (standard deviation 8.7), with 84.1% men and 88.3% having low income. Venlafaxine was significantly associated with a lower risk of withdrawal from substances (odds ratio 0.35, 95% confidence interval 0.13 to 0.96). However, we found no association between the recent use of venlafaxine and all-cause mortality (1.08, 0.55 to 2.14). The point estimates were similar in a series of sensitivity analyses, though not all analyses statistical significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides strong ground for clinicians to consider the use of venlafaxine to reduce patient experiencing withdrawal symptoms from substances.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-026-01427-9","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T12:56:24Z","timestamp":1772456184000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between venlafaxine use and the risk of withdrawal from nonopioid substances: a nationwide, population-based study"],"prefix":"10.1186","volume":"23","author":[{"given":"Shyh-Yuh","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian Meng-Hsun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Hsiang-Te","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsuan-Yun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swu-Jane","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"1427_CR1","unstructured":"United Nations Office on Drugs and Crime U: World Drug Report 2023. United Nations publication, 2023."},{"key":"1427_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","volume":"5","author":"Collaborators GAaDU","year":"2018","unstructured":"Collaborators GAaDU. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry. 2018;5:987\u20131012.","journal-title":"Lancet Psychiatry"},{"key":"1427_CR3","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GRF Collaborators","year":"2020","unstructured":"Collaborators GRF. Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223\u201349.","journal-title":"Lancet"},{"key":"1427_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1365-2125.2012.04474.x","volume":"77","author":"A Forray","year":"2014","unstructured":"Forray A, Sofuoglu M. Future pharmacological treatments for substance use disorders. Br J Clin Pharmacol. 2014;77:382\u2013400.","journal-title":"Br J Clin Pharmacol"},{"key":"1427_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drugalcdep.2014.02.024","volume":"138","author":"M Nuijten","year":"2014","unstructured":"Nuijten M, Blanken P, van den Brink W, Hendriks V. Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in the Netherlands. Drug Alcohol Depend. 2014;138:177\u201384.","journal-title":"Drug Alcohol Depend"},{"key":"1427_CR6","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/add.15242","volume":"116","author":"L Brandt","year":"2021","unstructured":"Brandt L, Chao T, Comer SD, Levin FR. Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer? Addiction. 2021;116:694\u2013710.","journal-title":"Addiction"},{"key":"1427_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40263-020-00711-x","volume":"34","author":"KJ Siefried","year":"2020","unstructured":"Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine\/amphetamine dependence: a systematic review. CNS Drugs. 2020;34:337\u201365.","journal-title":"CNS Drugs"},{"key":"1427_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00247-4","volume":"7","author":"JP Connor","year":"2021","unstructured":"Connor JP, Stjepanovi\u0107 D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7:16.","journal-title":"Nat Rev Dis Primers"},{"key":"1427_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1176\/appi.ajp.2012.12010112","volume":"170","author":"HM Pettinati","year":"2013","unstructured":"Pettinati HM, O\u2019Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170:23\u201330.","journal-title":"Am J Psychiatry"},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1081\/ADA-100100588","volume":"26","author":"DM McDowell","year":"2000","unstructured":"McDowell DM, Levin FR, Seracini AM, Nunes EV. Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse. 2000;26:25\u201331.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"1427_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15537\/smj.2019.4.23718","volume":"40","author":"YS Althobaiti","year":"2019","unstructured":"Althobaiti YS. Role of venlafaxine in relapse to methamphetamine seeking. Potential treatment option for drug dependence. Saudi Med J. 2019;40:339\u201346.","journal-title":"Saudi Med J"},{"issue":"Suppl 1","key":"1427_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1360-0443.2005.00985.x","volume":"100","author":"DA Ciraulo","year":"2005","unstructured":"Ciraulo DA, Sarid-Segal O, Knapp CM, Ciraulo AM, LoCastro J, Bloch DA, et al. Efficacy screening trials of paroxetine, pentoxifylline, riluzole, pramipexole and venlafaxine in cocaine dependence. Addiction. 2005;100(Suppl 1):12\u201322.","journal-title":"Addiction"},{"key":"1427_CR13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/add.12108","volume":"108","author":"FR Levin","year":"2013","unstructured":"Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction. 2013;108:1084\u201394.","journal-title":"Addiction"},{"key":"1427_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1521-0391.2013.12065.x","volume":"23","author":"WN Raby","year":"2014","unstructured":"Raby WN, Rubin EA, Garawi F, Cheng W, Mason E, Sanfilippo L, et al. A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. Am J Addict. 2014;23:68\u201375.","journal-title":"Am J Addict"},{"key":"1427_CR15","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.jsat.2009.12.009","volume":"38","author":"EA Wells","year":"2010","unstructured":"Wells EA, Saxon AJ, Calsyn DA, Jackson TR, Donovan DM. Study results from the Clinical Trials Network\u2019s first 10 years: where do they lead? J Subst Abuse Treat. 2010;38:S14\u201330.","journal-title":"J Subst Abuse Treat"},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamapsychiatry.2022.3788","volume":"80","author":"M Hartikainen","year":"2023","unstructured":"Hartikainen M, Taipale H, Tanskanen A, Mittendorfer-Rutz E, L\u00e4hteenvuo M, Tiihonen J. Association of pharmacological treatments and hospitalization and death in individuals with amphetamine use disorders in a Swedish nationwide cohort of 13 965 patients. JAMA Psychiatr. 2023;80:31\u20139.","journal-title":"JAMA Psychiatr"},{"key":"1427_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/EDE.0b013e31821d09cd","volume":"22","author":"S Wang","year":"2011","unstructured":"Wang S, Linkletter C, Maclure M, Dore D, Mor V, Buka S, et al. Future cases as present controls to adjust for exposure trend bias in case-only studies. Epidemiology. 2011;22:568\u201374.","journal-title":"Epidemiology"},{"key":"1427_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076045","volume":"382","author":"WC Huang","year":"2023","unstructured":"Huang WC, Yang AS, Tsai DH, Shao SC, Lin SJ, Lai EC. Association between recently raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control study. BMJ. 2023;382:e076045.","journal-title":"BMJ"},{"key":"1427_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"CY Hsieh","year":"2019","unstructured":"Hsieh CY, Su CC, Shao SC, Sung SF, Lin SJ, Kao Yang YH, et al. Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol. 2019;11:349\u201358.","journal-title":"Clin Epidemiol"},{"key":"1427_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2147\/CLEP.S426485","volume":"15","author":"DH Tsai","year":"2023","unstructured":"Tsai DH, Bell JS, Abtahi S, Baak BN, Bazelier MT, Brauer R, et al. Cross-regional data initiative for the assessment and development of treatment for neurological and mental disorders. Clin Epidemiol. 2023;15:1241\u201352.","journal-title":"Clin Epidemiol"},{"key":"1427_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/ebmental-2021-300300","volume":"25","author":"CL Huang","year":"2022","unstructured":"Huang CL, Tsai IJ, Lee CW. Risk of psychosis in illicit amphetamine users: a 10 year retrospective cohort study. Evid Based Ment Health. 2022;25:163\u20138.","journal-title":"Evid Based Ment Health"},{"key":"1427_CR22","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1111\/add.15337","volume":"116","author":"WH Pan","year":"2021","unstructured":"Pan WH, Wu KC, Chen CY, Chu YR, Wu SC, Jou S, et al. First-time offenders for recreational ketamine use under a new penalty system in Taiwan: incidence, recidivism and mortality in national cohorts from 2009 to 2017. Addiction. 2021;116:1770\u201381.","journal-title":"Addiction"},{"key":"1427_CR23","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1007\/s11469-021-00745-2","volume":"21","author":"C-L Huang","year":"2023","unstructured":"Huang C-L, Tsai I-J, Lin W-C, Wang R-Y, Chuang JP-C, Lee CW-S, et al. People who used illicit drugs had higher rates of road traffic accidents: a population-based study in Taiwan, 2007\u20132016. Int J Ment Health Addict. 2023;21:2666\u201381.","journal-title":"Int J Ment Health Addict"},{"key":"1427_CR24","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/joim.12186","volume":"275","author":"J Hallas","year":"2014","unstructured":"Hallas J, Potteg\u00e5rd A. Use of self-controlled designs in pharmacoepidemiology. J Intern Med. 2014;275:581\u20139.","journal-title":"J Intern Med"},{"key":"1427_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/pds.5227","volume":"30","author":"SM Cadarette","year":"2021","unstructured":"Cadarette SM, Maclure M, Delaney JAC, Whitaker HJ, Hayes KN, Wang SV, et al. Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2021;30:671\u201384.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1427_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.jacc.2018.06.067","volume":"72","author":"CC Lee","year":"2018","unstructured":"Lee CC, Lee MG, Hsieh R, Porta L, Lee WC, Lee SH, et al. Oral fluoroquinolone and the risk of aortic dissection. J Am Coll Cardiol. 2018;72:1369\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"1427_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/YIC.0000000000000487","volume":"39","author":"MM Bassiony","year":"2024","unstructured":"Bassiony MM, Abdelfattah NR, Elshabrawy A, Adly MM. A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. Int Clin Psychopharmacol. 2024;39:341\u20139.","journal-title":"Int Clin Psychopharmacol"},{"key":"1427_CR28","first-page":"Cd006528","volume":"12","author":"N Watanabe","year":"2011","unstructured":"Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2011;12:Cd006528.","journal-title":"Cochrane Database Syst Rev"},{"key":"1427_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/jech-2025-223903","volume":"79","author":"SY Wei","year":"2025","unstructured":"Wei SY, Li BM, Hu HY, Tsai DH, Lin SJ, Lin SY, et al. Detection of hidden populations using illicit substances. J Epidemiol Community Health. 2025;79:719\u201325.","journal-title":"J Epidemiol Community Health"},{"key":"1427_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00001648-199505000-00010","volume":"6","author":"S Suissa","year":"1995","unstructured":"Suissa S. The case-time-control design. Epidemiology. 1995;6:248\u201353.","journal-title":"Epidemiology"},{"key":"1427_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0962280208092347","volume":"18","author":"PG Arbogast","year":"2009","unstructured":"Arbogast PG, Ray WA. Use of disease risk scores in pharmacoepidemiologic studies. Stat Methods Med Res. 2009;18:67\u201380.","journal-title":"Stat Methods Med Res"},{"key":"1427_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103295","volume":"97","author":"A Bahji","year":"2021","unstructured":"Bahji A, Meyyappan AC, Hawken ER, Tibbo PG. Pharmacotherapies for cannabis use disorder: a systematic review and network meta-analysis. Int J Drug Policy. 2021;97:103295.","journal-title":"Int J Drug Policy"},{"key":"1427_CR33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000506868","volume":"89","author":"F Cosci","year":"2020","unstructured":"Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89:283\u2013306.","journal-title":"Psychother Psychosom"},{"key":"1427_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.06.040","volume":"144","author":"MA Kelly","year":"2014","unstructured":"Kelly MA, Pavlicova M, Glass A, Mariani JJ, Bisaga A, Sullivan MA, et al. Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR? Drug Alcohol Depend. 2014;144:42\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"1427_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.110958","volume":"251","author":"Z Gao","year":"2023","unstructured":"Gao Z, Winhusen TJ, Gorenflo M, Ghitza UE, Nunes E, Saxon AJ, et al. Potential effect of antidepressants on remission from cocaine use disorder - a nationwide matched retrospective cohort study. Drug Alcohol Depend. 2023;251:110958.","journal-title":"Drug Alcohol Depend"},{"key":"1427_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111018","volume":"253","author":"H Bakouni","year":"2023","unstructured":"Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, et al. Bupropion for treatment of amphetamine-type stimulant use disorder: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. Drug Alcohol Depend. 2023;253:111018.","journal-title":"Drug Alcohol Depend"},{"key":"1427_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.20882\/adicciones.1559","volume":"34","author":"M Torrens","year":"2022","unstructured":"Torrens M, Tirado-Mu\u00f1oz J, Fonseca F, Farr\u00e9 M, Gonz\u00e1lez-Pinto A, Arrojo M, et al. Clinical practice guideline on pharmacological and psychological management of adult patients with depression and a comorbid substance use disorder. Adicciones. 2022;34:128\u201341.","journal-title":"Adicciones"},{"key":"1427_CR38","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association D, Association AP: Diagnostic and statistical manual of mental disorders: DSM-5. American psychiatric association Washington, DC; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1427_CR39","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.drugalcdep.2011.04.015","volume":"118","author":"T Zorick","year":"2011","unstructured":"Zorick T, Sugar CA, Hellemann G, Shoptaw S, London ED. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug Alcohol Depend. 2011;118:500\u20133.","journal-title":"Drug Alcohol Depend"},{"key":"1427_CR40","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1192\/bjp.183.4.304","volume":"183","author":"T Weaver","year":"2003","unstructured":"Weaver T, Madden P, Charles V, Stimson G, Renton A, Tyrer P, et al. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry. 2003;183:304\u201313.","journal-title":"Br J Psychiatry"},{"key":"1427_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-021-00354-1","volume":"16","author":"CF Aas","year":"2021","unstructured":"Aas CF, Vold JH, Gjestad R, Skurtveit S, Lim AG, Gjerde KV, et al. Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway. Subst Abuse Treat Prev Policy. 2021;16:1\u201310.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"1427_CR42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addbeh.2015.05.001","volume":"48","author":"J Burdzovic Andreas","year":"2015","unstructured":"Burdzovic Andreas J, Lauritzen G, Nordfjaern T. Co-occurrence between mental distress and poly-drug use: a ten year prospective study of patients from substance abuse treatment. Addict Behav. 2015;48:71\u20138.","journal-title":"Addict Behav"},{"key":"1427_CR43","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1600-0447.1985.tb01271.x","volume":"71","author":"MB Holmberg","year":"1985","unstructured":"Holmberg MB. Longitudinal studies of drug abuse in a fifteen-year-old population. 3. Hidden drug abuse. Acta Psychiatr Scand. 1985;71:197\u2013200.","journal-title":"Acta Psychiatr Scand"},{"key":"1427_CR44","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1111\/add.15458","volume":"116","author":"P Reuter","year":"2021","unstructured":"Reuter P, Caulkins JP, Midgette G. Heroin use cannot be measured adequately with a general population survey. Addiction. 2021;116:2600\u20139.","journal-title":"Addiction"},{"key":"1427_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.208955","volume":"151","author":"MC Huang","year":"2023","unstructured":"Huang MC, Fang SC, Lin C, Lin T, Chang HM, Yang TW, et al. Risk factors for relapse among methamphetamine users receiving a joint legal-medical treatment program as a diversion intervention: a one-year follow-up study. J Subst Use Addict Treat. 2023;151:208955.","journal-title":"J Subst Use Addict Treat"},{"key":"1427_CR46","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383\u20138.","journal-title":"Epidemiology"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01427-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:04:26Z","timestamp":1775574266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01427-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01427-9","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board for the Protection of Human Subjects at Antai Medical Care Corporation (approval number: 22-105-A). There was no requirement for informed consent from the participants described in the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}